What is it about?
Candida is a yeast that can cause life-threatening infections in HIV-infected individuals. A novel compound (K21) was tested to see if it is effective in stopping the growth or killing different species of Candida, including those found to be resistant to currently dispensed drugs.
Why is it important?
Antifungal drug resistance is on the increase and new treatment options are needed to effectively treat infections. Our results showed that K21 acts as a strong antifungal, both on its own and in combination with fluconazole, one of the most widely dispensed antifungal drugs.
Read the Original
This page is a summary of: K21 Compound, a Potent Antifungal Agent: Implications for the Treatment of Fluconazole-Resistant HIV-Associated Candida Species, Frontiers in Microbiology, May 2019, Frontiers, DOI: 10.3389/fmicb.2019.01021.
You can read the full text:
The following have contributed to this page